Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi

Autor(es)

Guido, Rafael V. C. ^[1] ; Trossini, Gustavo H. G. ^[2] ; Castilho, Marcelo S. ^[3] ; Oliva, Glaucius ^[1] ; Ferreira, Elizabeth I. ^[2] ; Andricopulo, Adriano D. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Biotecnol Mol Estrutural, Lab Quim Med & Computac, BR-13560970 Sao Carlos, SP - Brazil

^[2] Univ Sao Paulo, Fac Ciencias Farmaceut, Lab Planejamento & Sintese Quimioterap Potenciais, BR-05508900 Sao Paulo - Brazil

^[3] Univ Fed Bahia, Fac Farm, Lab Bioinformat & Modelagem Mol, BR-40170290 Salvador, BA - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Enzyme Inhibition and Medicinal Chemistry; v. 23, n. 6, p. 964-973, 2008.
• Área do conhecimento: Ciências da Saúde - Farmácia
• Citações Web of Science: 26
• Assunto(s): Química farmacêutica Terapêutica Doença de Chagas Trypanosoma cruzi Inibidores enzimáticos

Resumo

Chagas' disease is a parasitic infection widely distributed throughout Latin America, with devastating consequences in terms of human morbidity and mortality. Cruzain, the major cysteine protease from Trypanosoma cruzi, is an attractive target for antitrypanosomal chemotherapy. In the present work, classical two-dimensional quantitative structure-activity relationships (2D QSAR) and hologram QSAR (HQSAR) studies were performed on a training set of 45 thiosemicarbazone and semicarbazone derivatives as inhibitors of T. cruzi cruzain. Significant statistical models (HQSAR, q2 = 0.75 and r2 = 0.96; classical QSAR, q2 = 0.72 and r2 = 0.83) were obtained, indicating their consistency for untested compounds. The models were then used to evaluate an external test set containing 10 compounds which were not included in the training set, and the predicted values were in good agreement with the experimental results (HQSAR, = 0.95; classical QSAR, = 0.91), indicating the existence of complementary between the two ligand-based drug design techniques. (AU)

• Processo FAPESP: 01/01192-3 - Antichagásicos potenciais derivados de compostos nitro-heterocíclicos
• Beneficiário: Elizabeth Igne Ferreira
• Modalidade de apoio: Auxílio à Pesquisa - Temático